Formulary Watch |

FDA's Center for Drug Evaluation and Research approved fewer new treatments in 2019.

Global market for peanut allergy treatments estimate at $4.5 billion.

A new class of drugs for high cholesterol and a novel peanut allergy treatment lead expected approvals.

Novel cancer drug snags FDA approval.

Traditional party drug known as ecstasy is undergoing clinical trials to assist in PTSD treatment.

Lamotrigine was contaminated with a heart drug.

Ozempic’s approval follows Jardiance’s expanded heart indication last July.

Already approved for adult patients, Fiasp is now available for children.

Major depression drug recalled over wrong dosage.

Pfizer bucks the trend with as high as 98.5% price cuts.

Approval of Ubrelvy follows several new migraine drugs.

Diabetes and hypertension are among the primary diseases included.

The fish oil drug is approved to reduce cardiovascular risk. 

Alkermes omitted warnings about serious risks from taking the drug.

Stephen Hahn is confirmed by the U.S. Senate.

Hospitals sue over drug price disclosure rule.

This is the agency’s first generic approvals of Gilenya.

Approval made via international collaborative effort.

Federal subpoenas are latest in opioid actions.

FDA cites 15 companies making unsubstantiated health claims.

PBM mergers contribute to pricing problems, ACP says.

Trump claims lower drug prices, fights Pelosi bill.

FDA and Congress are putting forth new proposals to mitigate drug shortages, which continue to have a major impact on the US healthcare system.

Pharma maker develops biosimilars to Lucentis, Eyelea. 

Sandoz now has 2 biosimilars to the popular cancer drug.

Health groups had urged Trump to make a different choice.

PBM’s Medicare plan includes deep discounts

Researchers find lower lung function after inhaler change.

This is the eighth indication approved for Xarelto.

Here are the most exciting drugs in the pipeline right now.